A team of scientists in Italy has discovered the "hiding place" of HIV virus in cells that holds promise for important developments towards new therapies to cure the disease.
The team at the International Center for Genetic Engineering and Biotechnology (ICGEB) in the northern city of Trieste photographed the structure of nucleic lymphocites with a high-resolution microscopy technique, a statement from ICGEB said.
That the problem regarding AIDS is due to the property of the virus to insert its own DNA into that of the cells that it infects so that it becomes part of their genetic patrimony had been known for some time.
However, how the virus manages to "hide" from therapeutic drugs inside these genes has remained, until now, an enigma, Xinhua cited ICGEB director general Mauro Giacca as saying.
"Since the 2000s there had been databases of tens of thousands of human DNA sequences in which the HIV virus integrated, but for 15 years no one was able to discover what they had in common," he noted.
"We have found that their common characteristic is being in the outer shell of the nucleus in close correspondence with the nuclear pore," Giacca added.
This region, he explained, contains a series of cellular genes characterised by factors that hide the presence of the HIV virus.
In contrast, the virus strongly disfavours the regions in the nuclear lamin-associated domains and other regions located centrally in the nucleus.
Therefore, the discovery shows the manner in which it is the very architecture of the nucleus of the lymphocytes and the areas that the HIV virus chooses to localise that assists its concealment, Giacca said.
The breakthrough, which was published on the website of the journal Nature earlier this week, could lead to the development of new AIDS drugs aimed at impeding the virus' integration into these regions by targeting proteins of the nuclear pore.
Since the beginning of the 1980s, when the AIDS epidemic started to diffuse, almost 80 million people have been infected by the virus, according to the World Health Organization (WHO) estimates, but not even one of these has been able to be completely cured.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
